| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥348.7B | ¥352.0B | -0.9% |
| Operating Income | ¥45.7B | ¥50.0B | -8.6% |
| Ordinary Income | ¥45.8B | ¥50.5B | -9.3% |
| Net Income | ¥33.2B | ¥39.6B | -16.1% |
| ROE | 8.4% | 10.4% | - |
FY2026 Q3 cumulative results: Revenue 348.7B yen (YoY -0.9%), Operating Income 45.7B yen (YoY -8.6%), Ordinary Income 45.8B yen (YoY -9.3%), Net Income 33.2B yen (YoY -16.1%). Revenue remained nearly flat while profitability deteriorated across all levels, with net income showing the largest decline at -16.1%. The company maintains a strong balance sheet with equity ratio of 71.9% and current ratio of 270.8%, but cash position declined 30.4% YoY to 58.6B yen. Operating margin compressed 2.4pt from 14.2% to 13.1% due to gross profit margin pressure and SG&A expense increases. The Chemicals segment, representing 92.6% of revenue, experienced revenue decline of 3.5% and operating profit decline of 10.7%, driving overall performance weakness. Device System segment revenue grew 47.5% but remains in operating loss at -31M yen.
Revenue of 348.7B yen decreased 0.9% YoY, driven by the Chemicals segment decline of 3.5% to 323.4B yen, partially offset by Device System segment growth of 47.5% to 25.8B yen. The Chemicals segment accounts for 92.6% of total revenue, making it the primary driver of overall performance. Gross profit of 117.3B yen yielded a margin of 33.6%, down 0.8pt from prior year's 33.4%, as cost of sales increased relative to revenue. SG&A expenses rose 5.8% YoY to 71.6B yen, expanding the SG&A ratio from 19.2% to 20.5%, reflecting increased overhead costs that compressed operating profitability. Operating income of 45.7B yen declined 8.6% YoY with operating margin contracting 1.1pt to 13.1%.
Non-operating items showed minimal net impact, with non-operating income of 1.6B yen (including FX gains of 0.3B yen) offsetting non-operating expenses of 1.6B yen (interest expense 0.7B yen, commission fees 0.7B yen). Ordinary income of 45.8B yen reflected a 9.3% YoY decline. Extraordinary losses of 3.1B yen significantly impacted bottom-line results, primarily consisting of loss on valuation of securities of 2.6B yen and loss on disposal of assets of 0.4B yen. These non-recurring factors reduced profit before tax to 42.6B yen. After income tax expense of 9.4B yen (effective tax rate 22.1%), net income reached 33.2B yen, down 16.1% YoY. The gap between operating income decline of 8.6% and net income decline of 16.1% reflects the impact of extraordinary losses as non-recurring factors.
This represents a revenue flat/profit down pattern, where top-line stability masked significant profitability challenges from cost structure deterioration and non-recurring losses.
The Chemicals segment generated revenue of 323.4B yen (92.6% of total) and operating income of 45.9B yen with margin of 14.2%. As the core business, this segment experienced revenue decline of 3.5% YoY and operating profit decline of 10.7%, demonstrating margin compression. The Device System segment recorded revenue of 25.8B yen (7.4% of total) with operating loss of 0.3B yen (margin -1.2%). While Device System achieved substantial revenue growth of 47.5% YoY, it remains unprofitable, though the operating loss narrowed significantly from -147M yen to -31M yen. The 15.4pt margin differential between segments (Chemicals 14.2% vs Device System -1.2%) highlights the profitability disparity, with Chemicals providing nearly all operating profit while Device System continues restructuring toward breakeven.
[Profitability] ROE of 8.4% reflects net profit margin of 9.5%, asset turnover of 0.632, and financial leverage of 1.39x through DuPont decomposition. Operating margin of 13.1% contracted 1.1pt YoY from 14.2%, indicating cost structure pressure. Gross profit margin of 33.6% remained relatively stable. The company's ROE of 8.4% aligns with the upper quartile of industry peers. [Cash Quality] Cash and deposits of 58.6B yen plus short-term investment securities of 95.0B yen provide total liquid assets of 153.6B yen, covering short-term debt of 16.9B yen by 9.1x. However, cash position declined 25.6B yen (-30.4%) YoY, warranting attention. [Investment Efficiency] Asset turnover of 0.632 indicates moderate asset utilization. Total assets of 551.5B yen increased 1.9% YoY while revenue declined, suggesting efficiency deterioration. [Financial Health] Equity ratio of 71.9% (up 1.9pt from 70.2%) reflects conservative capitalization. Current ratio of 270.8% and quick ratio of 235.6% demonstrate strong short-term solvency. Total debt of 29.9B yen comprises short-term loans of 16.9B yen and long-term loans of 13.1B yen, with debt-to-equity ratio of 0.075 indicating minimal leverage. Interest coverage of 62.9x confirms comfortable debt servicing capacity.
Cash and deposits decreased 25.6B yen YoY to 58.6B yen, representing a substantial 30.4% decline that requires close monitoring despite strong overall liquidity metrics. Working capital movements show trade receivables increasing 19.9B yen to 106.7B yen, suggesting collection cycle extension and potential DSO deterioration. Inventories rose 5.8B yen to 46.0B yen, with finished goods increasing 5.8B yen, indicating potential demand softness or production planning issues. Trade payables declined 1.3B yen to 68.0B yen, reducing supplier credit utilization. The combination of rising receivables and inventories alongside declining payables consumed significant operating cash. Short-term investment securities increased 20.0B yen to 95.0B yen, partially offsetting cash decline through liquid asset reallocation. Total liquid assets (cash plus short-term securities) of 153.6B yen maintain adequate coverage of current liabilities at 1.18x. Property, plant and equipment declined 1.0B yen to 179.1B yen, suggesting moderate net capital investment. Retained earnings increased 22.3B yen to 283.2B yen, reflecting profit accumulation net of dividends. The 25.6B yen cash decline against net income of 33.2B yen implies negative operating cash conversion, with working capital increases and capital allocation absorbing earnings.
Ordinary income of 45.8B yen versus operating income of 45.7B yen shows near-zero non-operating contribution of approximately 0.1B yen, indicating minimal impact from financial activities. Non-operating income of 1.6B yen consisted primarily of FX gains of 0.3B yen and interest/dividend income of 0.5B yen, while non-operating expenses of 1.6B yen included interest expense of 0.7B yen and commission fees of 0.7B yen, resulting in a balanced non-operating position. Non-operating items represent 0.5% of revenue, demonstrating core business earnings dominate results. Extraordinary losses of 3.1B yen (0.9% of revenue) significantly impacted final profitability, with securities valuation loss of 2.6B yen representing non-recurring financial asset write-downs. Comprehensive income of 26.7B yen fell 6.5B yen short of net income of 33.2B yen, with the gap primarily attributable to FX translation adjustment loss of 6.4B yen from overseas operations. The 19.6% differential between comprehensive income and net income highlights exposure to foreign currency volatility through consolidated subsidiaries. Without direct operating cash flow disclosure, the 30.4% cash decline against positive net income suggests working capital deterioration and potential earnings quality concerns requiring investigation of accruals and receivables/inventory management.
Full-year guidance of revenue 485.0B yen, operating income 60.0B yen, and net income 40.0B yen implies Q4 requirements of revenue 136.3B yen, operating income 14.3B yen, and net income 6.8B yen. Q3 cumulative progress rates stand at revenue 71.9%, operating income 76.2%, and net income 83.0% versus full-year targets. Operating income progress of 76.2% exceeds the standard 75% benchmark for Q3, suggesting slight over-delivery in the first nine months. Net income progress of 83.0% is notably ahead of schedule, though this reflects lower Q4 earnings expectations rather than exceptional Q3 performance. The implied Q4 operating margin of 10.5% (14.3B yen / 136.3B yen) would represent significant deterioration from Q3 cumulative margin of 13.1%, indicating management anticipates seasonal or business condition weakness in the final quarter. The guidance assumes no revision this quarter, maintaining YoY comparisons of revenue +1.8%, operating income -5.5%, and ordinary income -6.9% for the full year. Achieving the unchanged forecast requires Q4 revenue growth of 64% QoQ with operating income declining to one-third of Q3 levels, creating execution risk if business conditions do not support the expected Q4 revenue acceleration.
Annual dividend of 125 yen per share was paid at year-end FY2025 (prior to 2-for-1 stock split effective April 1, 2025). Post-split, the company forecasts annual dividend of 75 yen for FY2026, representing effective continuation after adjusting for the split. Based on FY2026 net income guidance of 40.0B yen and 16.6M shares outstanding, forecasted EPS of 241.34 yen yields payout ratio of 31.1% (75 yen / 241.34 yen). Using Q3 cumulative actual EPS of 200.23 yen, the planned 75 yen dividend would represent payout ratio of 37.5%. The dividend revision flag indicates adjustment this quarter, consistent with the stock split recalibration. With no share buyback disclosure, total shareholder return relies solely on dividends. The payout ratio in the 30-40% range maintains conservative distribution policy with substantial earnings retention for reinvestment. Cash position of 58.6B yen covers indicated annual dividend payment of approximately 12.4B yen by 4.7x, though the 30.4% YoY cash decline and working capital consumption warrant monitoring of dividend sustainability in relation to free cash flow generation.
Chemicals segment concentration risk: With 92.6% of revenue and virtually all operating profit derived from the Chemicals segment, business performance exhibits high sensitivity to chemical industry demand cycles, raw material price volatility, and competitive dynamics. Any adverse developments in chemical markets would directly impact consolidated results with minimal diversification buffer.
Working capital deterioration risk: Trade receivables increased 19.9B yen YoY while cash declined 25.6B yen, indicating collection cycle extension and potential customer credit quality issues. Inventory accumulation of 5.8B yen suggests demand softness or production inefficiency. Continued working capital deterioration would pressure cash generation and potentially constrain capital allocation flexibility for dividends and investment.
Foreign currency translation exposure: Comprehensive income of 26.7B yen fell 6.5B yen below net income due to FX translation adjustment loss of 6.4B yen, representing 19.6% comprehensive income variance. This demonstrates significant balance sheet exposure to currency movements through overseas subsidiaries, creating volatility in reported equity and comprehensive income independent of operating performance.
[Industry Position] (Reference - Proprietary Analysis) The company's profitability metrics position favorably within the manufacturing sector. ROE of 8.4% matches the industry upper quartile benchmark of 8.4% (median 5.8%), indicating above-average return generation. Operating margin of 13.1% exceeds the industry median of 8.9%, placing the company in the upper performance tier for operational efficiency. Net profit margin of 9.5% substantially surpasses the industry median of 6.5%, confirming strong bottom-line conversion. Financial health indicators show conservative positioning with equity ratio of 71.9% well above the industry median of 63.8%, reflecting lower financial leverage. Current ratio of 270.8% significantly exceeds the industry median of 287.0%, demonstrating superior liquidity though both indicate strong short-term solvency. Asset turnover of 0.632 exceeds the industry median of 0.56, suggesting more efficient asset utilization. Revenue growth of -0.9% underperforms the industry median of +2.8%, highlighting top-line pressure relative to peers. The company demonstrates above-median profitability and financial strength within the manufacturing sector, though revenue growth lags industry trends.
(Industry: Manufacturing sector, Comparison: FY2025 Q3 period, Source: Proprietary analysis)
Profitability compression amid revenue stability: While revenue declined only 0.9% YoY, operating income fell 8.6% and net income declined 16.1%, demonstrating significant operating leverage weakness. The 1.1pt operating margin contraction from cost structure deterioration and 3.1B yen extraordinary losses highlight vulnerability to expense inflation and asset quality issues. The divergence between top-line resilience and bottom-line erosion suggests structural profitability challenges requiring management action on cost efficiency and product mix optimization.
Strong balance sheet with emerging cash flow concerns: The company maintains financial fortress characteristics with 71.9% equity ratio, 270.8% current ratio, and minimal debt leverage (7.5% debt-to-equity). However, the 30.4% YoY cash decline to 58.6B yen, rising receivables of 19.9B yen, and inventory accumulation of 5.8B yen signal working capital management deterioration. The disconnect between strong balance sheet structure and weakening cash generation warrants scrutiny of operating cash flow quality and sustainability of the 37.5% dividend payout ratio without confirmed free cash flow adequacy.
Chemicals segment dependency and Device System transition: With 92.6% revenue concentration in Chemicals and 14.2% segment margin versus Device System's -1.2% margin, earnings stability depends heavily on chemical industry conditions. Device System's 47.5% revenue growth and operating loss improvement from -147M yen to -31M yen demonstrates progress toward profitability, but contribution remains immaterial. Successful Device System turnaround and business diversification beyond Chemicals concentration represent medium-term structural improvement opportunities that could enhance earnings stability and growth trajectory.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.